IXC
Director Trades
| Date | Director | Value |
|---|
Company News
Invex Therapeutics receives tax rebate for neurological drug research
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced it has received about £100,000 (A$186,000) in a research and development tax rebate from the UK government for the 2021 financial year. The rebate relates to research and development activities conducted by its subsidiary Invex UK, including research undertaken in the lead-up to a planned phase three […]
Invex Therapeutics opens first US clinical site for Presendin trials
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced the opening of its first US-based clinical site at the Eye Wellness Centre in Texas. The centre is run by respected neuro-ophthalmologist Dr Rose Tang and will be integral to trials of the company’s lead candidate Presendin (sustained-release Exenatide) for neurological conditions relating to raised intracranial […]
Invex Therapeutics gets EU approval to develop Presendin for adolescents with idiopathic intracranial hypertension
A paediatric investigation plan (PIP) submitted by Invex Therapeutics (ASX: IXC) for the development of lead drug Presendin in the treatment of idiopathic intracranial hypertension (IIH) in adolescents has been accepted by the European Medicines Agency. The approval will allow Invex to develop Presendin for IIH patients who are under 18 years of age and […]
Invex Therapeutics to begin recruiting IIH patients in NZ for clinical trial following regulatory approvals
Invex Therapeutics (ASX: IXC) has secured approval to expand its Evolve phase III clinical trial into New Zealand, where it will evaluate its drug Presendin in patients with idiopathic intracranial hypertension (IIH). The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) granted approval for the trial along with Invex getting the green light from […]
Invex Therapeutics opens Australian and UK sites for phase III trial of Presendin for idiopathic intracranial hypertension
Biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced the opening of clinical sites in Australia and the UK, allowing patient screening and recruitment to commence immediately for its Evolve phase III trial of lead drug Presendin to treat neurological conditions relating to raised intracranial pressure. The Australian site is located at the Adelaide offices of […]
Invex Therapeutics recruits first idiopathic intracranial hypertension patient to Presendin trial
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has randomised the first idiopathic intracranial hypertension (IIH) patient into its IIH Evolve Phase III clinical trial using lead drug Presendin. The patient was recruited at VisionSA in South Australia, and other clinical trial sites have since become active and open for recruitment in Australia and the UK. […]
Invex Therapeutics closes September quarter focused on lead drug Presendin
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has rounded out a September quarter focused on the continued development and commercialisation of lead candidate Presendin for the treatment of neurological conditions related to raised intracranial pressure. In its latest quarterly report, the company said it had invested time and resources into preparation of an Evolve phase […]
Invex Therapeutics opens up more trial sites with second Australian ethics approval
Invex Therapeutics (ASX: IXC) has secured its second Human Research Ethics Committee (HREC) approval in Australia to begin its phase III trial evaluating its lead drug Presendin in patients with idiopathic intracranial hypertension (IIH). The second HREC approval covers three additional public hospitals: the Alfred Hospital in Melbourne and Liverpool and Sydney Eye in Sydney. […]
Invex Therapeutics to begin patient recruitment for phase III Presendin trial in IIH
Invex Therapeutics (ASX: IXC) will begin a phase III clinical trial of its drug Presendin after locking-in approval along with investigational new drug (IND) status from the United States Food and Drug Administration. The IIH EVOLVE phase III trial will be undertaken in the US and evaluate Presendin in patients with idiopathic intracranial hypertension (IIH). […]
Invex Therapeutics in strong position to launch Presendin trials
Invex Therapeutics (ASX: IXC) has confirmed its strong financial position as it gets set to commence recruitment for phase three clinical trials of lead drug Presendin on patients with newly diagnosed idiopathic intracranial hypertension (IIH). In its June quarterly report released today, the clinical-stage biopharmaceutical company declared it is fully funded to complete the trial […]
